Datum Källa Rubrik Typ Alternativ
2023-01-10 Promore Pharma BioStock: Promore Pharmas vd om förhoppningarna för 2023 Pressreleaser Visa Stäng
2023-01-10 Promore Pharma BioStock: Promore Pharma's CEO on hopes for 2023 Pressreleaser Visa Stäng
2022-12-08 Västra Hamnen Market Focus Västra Hamnen Market Focus: Promore Pharma: Inväntar resultat Analyser Visa Stäng
2022-11-29 Promore Pharma Interim report January - September 2022 Analyser Ladda ner | Visa Stäng
2022-11-29 Promore Pharma Delårsrapport januari – september 2022 Analyser Ladda ner | Visa Stäng
2022-11-24 Promore Pharma Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022 Analyser Ladda ner | Visa Stäng
2022-11-24 Promore Pharma Inbjudan till presentation av Promore Pharmas delårsrapport för Q3 2022 Analyser Ladda ner | Visa Stäng
2022-11-23 Promore Pharma Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma Analyser Ladda ner | Visa Stäng
2022-11-23 Promore Pharma Valberedning utsedd inför årsstämma 2023 i Promore Pharma Analyser Ladda ner | Visa Stäng
2022-11-15 Analysguiden Analysguiden: ANALYS Promore Pharma: Resultat från fas 2 mot ärrbildning i april 2023 Analyser Ladda ner | Visa Stäng
2022-11-01 Promore Pharma Promore Pharma uppdaterar om sin kliniska Fas II-studie med ensereptide Analyser Ladda ner | Visa Stäng
2022-11-01 Promore Pharma Promore Pharma provides an update on the Phase II clinical trial with ensereptide Analyser Ladda ner | Visa Stäng
Analyser | 1 Nov 2022 | Promore Pharma

Promore Pharma provides an update on the Phase II clinical trial with ensereptide

STOCKHOLM, 1 November 2022 – Today, Promore Pharma AB announces that the results from the company’s phase II study PHSU05 with ensereptide for prevention of skin scarring is expected to be available in April 2023. The clinical part of the trial was completed according to plan earlier this year, but the limited availability of qualified personnel and specialized image analysis equipment results in a slightly longer duration of the subsequent histopathological analysis than originally expected.

The company’s ensereptide program is currently focused on the prevention of skin scarring associated with surgery or trauma. In the spring, a total of 24 subjects completed the clinical study protocol according to plan in the phase II study with ensereptide, PHSU05. In this study, Promore Pharma hopes to demonstrate that treatment with ensereptide reduces the likelihood of scarring on the skin. At the last clinic visit, biopsies were collected that are being analyzed with advanced histological methods during the autumn and fall of 2022/2023. However, the limited availability of qualified personnel and specialized image analysis equipment has caused a few weeks’ shift in the original timeline. A final study report with results from the trial is expected in April 2023.

“Our clinical study PHSU05 has so far progressed entirely according to our plan in all parts that we can influence. Access to advanced equipment for digital image analysis at our service providers means that we are forced to carry out certain analysis steps serially rather than in parallel. This means a minor time shift until we can unblind the data and compile final results. However, we would like to emphasize that this does not have any negative impact on the quality of the study execution,” says Jonas Ekblom, CEO of Promore Pharma.

The study is a double-blind, randomized phase II pilot study with the aim of evaluating ensereptide regarding (i) local tolerance, (ii) the application process for the experimental drug, as well as (iii) preliminary effect on scar prevention in healthy volunteers with experimental wounds. The clinical part of the study that was conducted at the Clinical Trial Consultants AB’s clinic in Uppsala was completed and a total of 24 subjects were included. Analysis of monitoring data from the clinical part of the study shows that the number of deviations from the study protocol has been few, and no major deviations were reported. The company expects to reach the milestone of Clean File in the project during the first quarter of 2023, which will be announced by the company. At that time, the timeline for subsequent work with the aim of achieving an outcome report can be determined with higher precision.

Scars appear after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically undesirable, and they can also cause itching, stiffness, sleep problems, anxiety, depression and create a negative impact on activities of daily life.

The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, is estimated at USD 25 billion annually with a yearly growth of about 10%, according to independent estimates. Today, there are no prescription pharmaceuticals for scar prevention.

2022-09-21 Promore Pharma BioStock: Promore Pharma's leg ulcer treatment to reduce patient suffering Pressreleaser Visa Stäng
2022-09-21 Promore Pharma BioStock: Promore Pharmas bensårsbehandling ska minska patientens lidande Pressreleaser Visa Stäng
2022-09-05 Promore Pharma BioStock: Promore Pharma advancing according to plan Pressreleaser Visa Stäng
2022-09-05 Promore Pharma BioStock: Promore Pharma avancerar enligt plan Pressreleaser Visa Stäng
2022-09-01 Västra Hamnen Market Focus Västra Hamnen Market Focus: Promore Pharma: Utvecklingsarbetet fortlöper Analyser Visa Stäng
2022-08-30 Promore Pharma Promore Pharma Interim report January – June 2022 Analyser Ladda ner | Visa Stäng
2022-08-30 Promore Pharma Promore Pharma Delårsrapport januari – juni 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Promore Pharma Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022 Analyser Ladda ner | Visa Stäng
2022-08-23 Promore Pharma Inbjudan till telefonkonferens om Promore Pharmas rapport för det andra kvartalet 2022 Analyser Ladda ner | Visa Stäng
2022-08-15 Promore Pharma BioStock: Promore Pharma stärker patentskyddet Pressreleaser Visa Stäng
2022-08-15 Promore Pharma BioStock: Promore Pharma strengthens IP-protection Pressreleaser Visa Stäng
2022-08-10 Promore Pharma Promore Pharma granted EU patent regarding treatment of chronic wounds Analyser Ladda ner | Visa Stäng
2022-08-10 Promore Pharma Promore Pharma beviljas patent i Europa avseende behandling av kroniska sår Analyser Ladda ner | Visa Stäng
2022-06-17 Promore Pharma BioStock: Sista klinikbesöket genomfört i Promore Pharmas ensereptide-studie Pressreleaser Visa Stäng
2022-06-17 Promore Pharma BioStock: Last clinic visit completed in Promore Pharma's ensereptide study Pressreleaser Visa Stäng
2022-06-14 Analysguiden Analysguiden: ANALYS Promore Pharma: Rekryteringsmål uppnått i fas 2 mot ärrbildning Analyser Ladda ner | Visa Stäng
2022-06-13 Promore Pharma The last clinic visit conducted in Promore Pharma's phase II study of ensereptide Analyser Ladda ner | Visa Stäng
2022-06-13 Promore Pharma Sista klinikbesöket genomfört i Promore Pharmas fas II-studie av ensereptide Analyser Ladda ner | Visa Stäng
2022-05-25 Promore Pharma BioStock: Promore Pharma's Q1 characterised by study progress Pressreleaser Visa Stäng
2022-05-25 Promore Pharma BioStock: Promore Pharmas Q1 präglat av studieavancemang Pressreleaser Visa Stäng
2022-05-18 Västra Hamnen Market Focus Västra Hamnen Market Focus: Promore Pharma: Ärrstudie fullrekryterad Analyser Visa Stäng
2022-05-17 Promore Pharma Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022 Analyser Ladda ner | Visa Stäng
2022-05-17 Promore Pharma Kommuniké från Promore Pharma AB:s årsstämma den 17 maj 2022 Analyser Ladda ner | Visa Stäng
2022-05-17 Promore Pharma Promore Pharma -- delårsrapport januari-mars 2022 Analyser Ladda ner | Visa Stäng
2022-05-17 Promore Pharma Promore Pharma -- interim report January-March 2022 Analyser Ladda ner | Visa Stäng
2022-05-16 Promore Pharma BioStock: Promore Pharma vill påskynda läkning av venösa bensår Pressreleaser Visa Stäng
2022-05-16 Promore Pharma BioStock: Promore Pharma aims to accelerate healing of venous leg ulcers Pressreleaser Visa Stäng
2022-05-13 Promore Pharma Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022 Analyser Ladda ner | Visa Stäng
2022-05-13 Promore Pharma Inbjudan till telefonkonferens om Promore Pharmas rapport för det första kvartalet 2022 Analyser Ladda ner | Visa Stäng
2022-04-26 Promore Pharma Promore Pharmas årsredovisning för 2021 samt stämmohandlingar publicerade Analyser Ladda ner | Visa Stäng
2022-04-26 Promore Pharma Promore Pharma’s Annual Report 2021 and AGM related Documents Published Analyser Ladda ner | Visa Stäng
2022-04-12 Promore Pharma KALLELSE TILL ÅRSSTÄMMA I PROMORE PHARMA AB (PUBL) Analyser Ladda ner | Visa Stäng
2022-04-12 Promore Pharma NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL) Analyser Ladda ner | Visa Stäng
2022-04-07 Promore Pharma BioStock: Promore Pharmas fas II-studie pågår planenligt Pressreleaser Visa Stäng
2022-04-07 Promore Pharma BioStock: Promore Pharma's phase II study running according to plan Pressreleaser Visa Stäng

Kommande händelser

28 Feb 2023 | Bokslutskommuniké 2022
23 May 2023 | Årsstämma 2022